At 7.1% CAGR, the APAC Laboratory Animal Diet Market is projected to be worth US$ 734.52 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the APAC laboratory animal diet market was valued at US$ 486.55 million in 2022 and is expected to reach US$ 734.52 million by 2028, registering a CAGR of 7.1% from 2022 to 2028. Rising demand for humanized mice models and growing inclination toward customized diet plan for laboratory animals are the critical factors attributed to the market expansion.

Basic research, safety assessment for large molecule therapeutics, simulation of some human-specific infectious diseases, and efficacy testing of immunotherapy approaches all use humanized mice models. The human protein is expressed in cells and tissues while the mouse protein is silenced. Humanized mice models are generally used to study cancer genetics, autoimmune diseases, regenerative medicine, human hematopoiesis, infectious diseases, transplantation, and autoimmunity. They enhance the translational value of preclinical research by enabling researchers to understand disease pathways better. Both mice and human genes and proteins are examined for the structure to determine the optimal expression and functionality of the human protein in a mouse environment. Recent models also reflect hematopoiesis, natural immunity, neurobiology, and molecular signaling pathways that influence disease pathobiology. These mice models also aid studies on human pathobiology, natural disease processes, and therapeutic efficacy across a broad spectrum of human diseases. Overall, humanized mice models offer low-cost, high-throughput studies on infection or degeneration in natural pathogen-host cells and the opportunity to test disease transmission and eradication. Humanized mice models have been xenografted with human cells or engineered to express human genes. These mice are used extensively to elucidate and understand human physiology and the etiology of human-specific infections. These models are used in biomedical research to develop therapeutics due to their numerous advantages, such as small size, short reproductive cycle, ease of handling, and increased genomic similarity to humans. They are crucial in preclinical research studies because they mimic several human-specific diseases and can be used to study the efficacy and safety of immunotherapy approaches. Humanized mice models have also played an important role in designing and developing vaccines and antibody-based therapies for COVID-19. The models, developed since the outbreak of COVID-19, could further help provide a more profound and better understanding of the infection and effectiveness of antiviral therapeutics and support the development of efficient drugs and therapies to treat the disease. Due to the reasons mentioned above, humanized mice models will continue to be widely used in the near future. Diet plays an important role in the immune response given by humans to a particular type of disease. Therefore, it is important to take care of the diet provided to the humanized mice model. Hence, humanized mice models are also given a diet similar to the human diet. The growing demand for humanized mice models will create an opportunity for the growth of the laboratory animal diet market.

On the contrary, high cost of laboratory animal diets due to maintenance and wastage hurdles the growth of APAC laboratory animal diet market.

Based on diet type, the APAC laboratory animal diet market is segmented into standard diets, irradiated diets, and autoclavable diets. The standard diets segment held 68.7% market share in 2022, amassing US$ 334.16 million. It is projected to garner US$ 497.45 million by 2028 to expand at 6.9% CAGR during 2022–2028.

Based on animal, the APAC laboratory animal diet market is segmented mouse, cat, dog, rabbit, chicken, and others. The mouse segment held 52.8% market share in 2022, amassing US$ 256.90 million. It is projected to garner US$ 396.14 million by 2028 to expand at 7.5% CAGR during 2022–2028.

Based on application, the APAC laboratory animal diet market is segmented into drug discovery and personalized medicines, regenerative medicines, pathology of infectious disease, drug toxicity and efficacy testing, and others. The drug discovery and personalized medicine segment held 49.9% market share in 2022, amassing US$ 242.56 million. It is projected to garner US$ 356.54 million by 2028 to expand at 6.6% CAGR during 2022–2028.

Based on end user, the APAC end user market is segmented into pharmaceutical & biopharmaceutical companies, research & academic institutes, and others. The pharmaceutical & biopharmaceutical companies segment held 64.1% market share in 2022, amassing US$ 311.84 million. It is projected to garner US$ 465.95 million by 2028 to expand at 6.9% CAGR during 2022–2028.

Based on country, the APAC laboratory animal diet market is segmented into China, Japan, India, Australia, South Korea, and the Rest of APAC. Our regional analysis states that China captured 29.3% market share in 2022. It was assessed at US$ 142.32 million in 2022 and is likely to hit US$ 212.64 million by 2028, exhibiting a CAGR of 6.9% during the forecast period.

Key players dominating the APAC laboratory animal diet market are Altromin Spezialfutter GmbH & Co. KG; Bio-Serv; Envigo; Krishna Valley Agrotech LLP; LabDiet; Research Diets Inc.; SAFE; Special Diet Services; and Specialty Feeds among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com